CLINICAL TRIALS PROFILE FOR PIROXICAM

All Clinical Trials for PIROXICAM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00530387 ↗	Multi-Centre European Photopatch Test Study	Completed	NHS Tayside	N/A	2008-07-01	It is known that people can develop an allergic skin reaction to a substance which is placed on the skin and then subjected to sunlight. This process is called Photocontact allergic dermatitis. It is known that people can develop Photocontact allergic dermatitis to sunscreen chemicals (filters) and also cream forms of pain-killing drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). The purpose of this study is to determine the frequency of Photocontact allergic dermatitis to 19 sunscreen filters and 5 topical NSAIDs in 1,000 European patients who present to a dermatologist with a sun-exposed site dermatitis. Each participant will have the 24 test agents plus one control of petrolatum applied to the skin of the back for 24 or 48 hours. After removal of the substances, the area of skin will be exposed to a precise amount of ultraviolet-A light. The area is then assessed 24, 48 and 72 hours later to see if a photocontact allergic reaction has occured. This method is known as photopatch testing. The study will run for one year, during which time it is planned to recruit 1,000 patients.
NCT00631514 ↗	Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Completed	Dr Ivancica Pavlicevic Family Practice Office	Phase 4	2005-01-01	NSAIDs may increase blood pressure and blunt the effects of many antihypertensives. Members of these drug classes differ in their propensity to such an interaction.
NCT00222183 ↗	Cutaneous Lupus Erythematosus and Elidel	Withdrawn	Novartis	N/A	2003-06-01	This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).
NCT00222183 ↗	Cutaneous Lupus Erythematosus and Elidel	Withdrawn	University of Leipzig	N/A	2003-06-01	This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).

Clinical Trial Conditions for PIROXICAM

Condition Name

Condition Name for PIROXICAM
Intervention	Trials
Postoperative Pain	3
Renal Colic	2
Pain	2
Contraception, Postcoital	1

Condition MeSH

Condition MeSH for PIROXICAM
Intervention	Trials
Pain, Postoperative	3
Pulpitis	3
Renal Colic	2
Toothache	2

Clinical Trial Locations for PIROXICAM

Trials by Country

+

−

Trials by Country for PIROXICAM
Location	Trials
Brazil	10
Tunisia	3
United Kingdom	2
Pakistan	2
Germany	2

Clinical Trial Progress for PIROXICAM

Clinical Trial Phase

Clinical Trial Phase for PIROXICAM
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	2
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for PIROXICAM
Clinical Trial Phase	Trials
Completed	18
Unknown status	5
Recruiting	3

Clinical Trial Sponsors for PIROXICAM

Sponsor Name

Sponsor Name for PIROXICAM
Sponsor	Trials
University of Monastir	3
Cairo University	3
Fundação de Amparo à Pesquisa do Estado de São Paulo	3

Sponsor Type

Sponsor Type for PIROXICAM
Sponsor	Trials
Other	33
Industry	5

Piroxicam: Clinical Trials, Market Analysis, and Projections

Introduction to Piroxicam

Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) widely used for the treatment of various inflammatory conditions, including arthritis, acute low back pain, and other chronic pain disorders. Here, we will delve into the clinical trials, market analysis, and projections for this versatile medication.

Clinical Trials and Efficacy

Acute Low Back Pain

A significant clinical trial involving 278 patients with acute low back pain demonstrated the efficacy of piroxicam. The trial, conducted by 27 investigators, showed that piroxicam provided statistically significant pain relief in lying, sitting, and standing positions after just three days of therapy. Although the difference in pain relief between piroxicam and placebo groups diminished by the seventh day, the piroxicam group required fewer additional analgesics and had a higher return-to-work rate[1].

Knee Osteoarthritis

A randomized clinical trial evaluated the effectiveness of piroxicam mesotherapy in treating knee osteoarthritis (KOA). The study found that mesotherapy with piroxicam was as effective as oral piroxicam in reducing pain and improving function in KOA patients over an 8-week period. Both treatment groups showed significant improvements in pain and function scores using the Visual Analogue Scale (VAS), Oxford Knee Score (OKS), and Western Ontario McMaster University Osteoarthritis Index (WOMAC)[4].

Market Analysis

Current Market Size and Growth

The global piroxicam market was valued at USD 3.09 billion in 2023 and is projected to reach USD 4.84 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.8% from 2024 to 2031. This growth is driven by the increasing prevalence of arthritis and other chronic inflammatory diseases, particularly among the aging population[3].

Market Segmentation

The piroxicam market is segmented based on application (pain management, inflammation treatment, arthritis treatment, muscle relaxation, and post-surgical care) and product form (oral tablets, capsules, topical gels, injectable, and suppositories). Geographically, the market spans North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa[3].

Key Drivers

• Increasing Prevalence of Chronic Conditions: The rising incidence of arthritis and other inflammatory diseases, especially among the elderly, is a significant driver.
• Advancements in Drug Formulations: Improvements in medication delivery systems and formulations have enhanced treatment options and accessibility.
• Expanding Healthcare Infrastructure: Growth in healthcare infrastructure in emerging markets has increased access to piroxicam and other NSAIDs[3][5].

Market Restraints

• Side Effects and Regulatory Concerns: Long-term use of NSAIDs like piroxicam can lead to gastrointestinal issues and cardiovascular risks, necessitating stringent regulatory controls.
• Competition from Alternative Therapies: The market faces competition from other pain relief therapies and drugs, which can impact demand for piroxicam[5].

Market Projections

Forecasted Growth

The piroxicam market is expected to continue its moderate growth trajectory, driven by the stable demand from chronic pain sufferers and the expanding geriatric population. The market size is projected to increase from USD 3.09 billion in 2023 to USD 4.84 billion by 2031[3].

Emerging Opportunities

• Improving Distribution Networks: Enhancing distribution channels in emerging markets can increase the reach and accessibility of piroxicam.
• Telemedicine and Online Pharmacies: The rise of telemedicine and online pharmacy platforms offers potential opportunities for market expansion, especially in underserved regions.
• Precision Medicine: Research into precision medicine, tailoring treatments based on genetic profiles, could lead to more personalized and effective use of piroxicam[5].

Competitive Landscape

The piroxicam market is competitive, with key players including AbbVie Inc., AstraZeneca plc, Bayer AG, GlaxoSmithKline plc, and Pfizer Inc., among others. These companies are focusing on innovative product developments, strategic partnerships, and expanding their presence in emerging markets[5].

Consumer and Patient Trends

Preference for Oral Dosage Forms

Consumers prefer oral dosage forms, which contributes to the sustained demand for piroxicam tablets. This preference is driven by ease of administration and patient compliance[5].

Government Initiatives

Government initiatives and funding for arthritis-related research have promoted the use of piroxicam and other NSAIDs, further driving market growth[5].

Key Takeaways

• Clinical Efficacy: Piroxicam has been shown to be effective in treating acute low back pain and knee osteoarthritis through various clinical trials.
• Market Growth: The global piroxicam market is projected to grow at a CAGR of 4.8% from 2024 to 2031, driven by increasing prevalence of chronic conditions and advancements in drug formulations.
• Market Segmentation: The market is segmented by application and product form, with a strong presence in North America, Europe, and the Asia-Pacific region.
• Emerging Opportunities: Improving distribution networks, telemedicine, and precision medicine offer significant opportunities for market expansion.

FAQs

What is piroxicam used for?

Piroxicam is used to treat various inflammatory conditions, including arthritis, acute low back pain, and other chronic pain disorders.

What are the key drivers of the piroxicam market?

The key drivers include the increasing prevalence of chronic conditions, advancements in drug formulations, and expanding healthcare infrastructure in emerging markets.

What are the potential side effects of long-term piroxicam use?

Long-term use of piroxicam can lead to gastrointestinal issues and cardiovascular risks, necessitating stringent regulatory controls.

How is the piroxicam market segmented?

The market is segmented based on application (pain management, inflammation treatment, etc.) and product form (oral tablets, capsules, etc.), as well as geographically across various regions.

What is the projected growth of the piroxicam market?

The global piroxicam market is projected to grow from USD 3.09 billion in 2023 to USD 4.84 billion by 2031, at a CAGR of 4.8%.

Which companies are key players in the piroxicam market?

Key players include AbbVie Inc., AstraZeneca plc, Bayer AG, GlaxoSmithKline plc, and Pfizer Inc., among others.

Sources

1. Treatment of acute low-back pain with piroxicam: results of a double-blind, parallel placebo-controlled trial. PubMed.
2. Piroxicam Market Report 2024 (Global Edition). Cognitive Market Research.
3. Piroxicam Market Size, Share, Growth & Trends [2024-2031]. Market Research Intellect.
4. Efficacy of Piroxicam Mesotherapy in Treatment of Knee Osteoarthritis: A Randomized Clinical Trial. Wiley Online Library.
5. Piroxicam Oral Tablets Market Size & Share 2025-2030. 360 Research Reports.